top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Anthony Scott Praill net worth and biography

Anthony Praill Biography and Net Worth

CFO of Kintara Therapeutics

Scott Praill, CPA, BSc. has been our Chief Financial Officer since January 29, 2013 and previously served as a consultant to Del Mar Pharmaceuticals (BC) Ltd. From 2004 to January 2013, Mr. Praill was an independent consultant providing accounting and administrative services to companies in the resource industry. Mr. Praill served as CFO of Strata Oil & Gas, Inc. from June 2007 to September 2008. From November 1999 to October 2003, Mr. Praill was Director of Finance at Inflazyme Pharmaceuticals Ltd. Mr. Praill completed his articling at Price Waterhouse (now PricewaterhouseCoopers LLP) and obtained his Chartered Professional Accountant designation in 1996. Mr. Praill obtained his Certified Public Accountant (Illinois) designation in 2001. Mr. Praill received a Financial Management Diploma (Honors), from the British Columbia Institute of Technology in 1993, and a Bachelor of Science from Simon Fraser University in 1989.

How do I contact Anthony Scott Praill?: The corporate mailing address for Mr. Praill and other Kintara Therapeutics executives is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. Kintara Therapeutics can also be reached via phone at (858) 350-4364 and via email at [email protected]. Learn More on Anthony Scott Praill's contact information.
Has Anthony Scott Praill been buying or selling shares of Kintara Therapeutics?: Anthony Scott Praill has not been actively trading shares of Kintara Therapeutics within the last three months. Most recently, on Wednesday, December 8th, Anthony Scott Praill bought 28,700 shares of Kintara Therapeutics stock. The stock was acquired at an average cost of $0.68 per share, with a total value of $19,516.00. Learn More on Anthony Scott Praill's trading history.
Who are Kintara Therapeutics' active insiders?: Kintara Therapeutics' insider roster includes Laura Johnson (Director), Anthony Praill (CFO), and Saiid Zarrabian (Insider). Learn More on Kintara Therapeutics' active insiders.

Anthony Scott Praill Insider Trading History at Kintara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/8/2021	Buy	28,700	$0.68	$19,516.00

Anthony Scott Praill Buying and Selling Activity at Kintara Therapeutics

Kintara Therapeutics Company Overview

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Today's Range

Now: $0.13

$0.11

$0.14

50 Day Range

MA: $0.11

$0.08

$0.16

2 Week Range

Now: $0.13

$0.08

$5.98

Volume

7,626,309 shs

Average Volume

13,357,169 shs

Market Capitalization

$5.18 million

P/E Ratio

N/A

Dividend Yield